Oxeia Biopharmaceuticals wins most innovative mTBI company award for 2026

By AI, Created 4:27 PM UTC, May 18, 2026, /AGP/ – Oxeia Biopharmaceuticals was named Global Health & Pharma’s Most Innovative Mild Traumatic Brain Injury Company 2026, marking a second straight year of recognition. The award comes as the Boston biotech prepares a larger Phase 2b trial of its concussion drug OXE103 and says its crowdfunding campaign has raised nearly $1.5 million.

Why it matters: - Oxeia Biopharmaceuticals is trying to turn a concussion therapy into a treatment for persistent post-concussion symptoms, a condition with limited options today. - The company’s latest award adds visibility as it seeks to move OXE103 into a larger clinical trial and attract more investors. - Board member Alex Smith said an effective concussion treatment is long overdue.

What happened: - Global Health & Pharma named Oxeia Biopharmaceuticals its Most Innovative Mild Traumatic Brain Injury Company 2026. - The recognition is the second straight year Oxeia has received the award. - The announcement was made May 15, 2026, in Boston. - Oxeia CEO Dr. Michael Wyand tied the award to interest in OXE103 and the company’s Regulation Crowdfunding campaign. - Oxeia said the crowdfunding campaign launched in early 2026, has raised nearly $1.5 million and remains open after an extension.

The details: - OXE103 is a form of human ghrelin, a naturally occurring hormone that crosses the blood-brain barrier. - The drug is being developed to treat persistent post-concussion symptoms by addressing metabolic disruption and brain injury after concussion. - Preclinical studies found OXE103 restored normal energy metabolism and reduced oxidative damage associated with brain injury. - In a Phase 2a pilot trial at the University of Kansas Medical Center, 85% of OXE103-treated patients responded, compared with 33% on standard care alone. - Improvements were seen across all study endpoints, including symptom severity and quality of life. - Through a licensing agreement, Oxeia gained access to Daiichi Sankyo clinical data covering 9 completed studies, more than 300 patients treated with ghrelin, 4 Phase 1 safety trials and an FDA-accepted open IND. - The FDA said in an initial regulatory meeting that no additional preclinical or safety studies would be required before advancing to Phase 2.

Between the lines: - The award gives Oxeia a marketing boost, but the real test is whether OXE103 can deliver in later-stage clinical trials. - The company is leaning on both clinical data and outside validation to support its pitch to investors and the concussion-treatment market. - Oxeia’s fundraising momentum suggests some public appetite for the story, but the investment remains speculative.

What’s next: - Oxeia plans to advance OXE103 into a 160-patient, multi-site, randomized, placebo-controlled Phase 2b trial. - The trial is expected to begin later in 2026. - The Regulation Crowdfunding offering remains open to additional investors after the extension. - Oxeia said its founding team has $9 billion in prior combined exits, including Arena Pharmaceuticals and Kythera Biopharmaceuticals. - More information is available on Oxeia Biopharmaceuticals.